prolia 60 mg 1 xeringa precarregada 1 ml
zytiga 500 mg 60 comprimits
nephromag 200 microgramos equipo de reactivos para preparacion radiofarmaceutica
rotop pharmaka gmbh - mertiatida - equipo de reactivos para preparaciÓn radiofarmacÉutica - 200 microgramos - mertiatida 200 microgramos - tecnecio (99mtc) mertiátida
oxigeno medicinal liquido solgroup 99,5% v/v gas para inhalacion
sol s.p.a. - oxigeno - gas criogÉnico medicinal - 99,5 % v/v - oxigeno 99.5 % v/v - oxígeno
oxigeno medicinal liquido solspa 99,5 % v/v gas para la inhalacion
sol s.p.a. - oxigeno - gas criogÉnico medicinal - 99,5% v/v - oxigeno 99.5 % v/v - oxígeno
oxigeno medicinal gas solgroup 99,5% v/v gas para inhalacion
sol s.p.a. - oxigeno - gas comprimido medicinal - 99,5% v/v - oxigeno 99,5 % v/v - oxígeno
ralydan 70 mg/70 mg aposito adhesivo medicamentoso
eurocept international bv - lidocaina, tetracaina - excipientes: sorbitan monopalmitato,parahidroxibenzoato de metilo,parahidroxibenzoato de propilo,pelicula no tejida cubierta con borato sodico - anestÉsicos locales - amidas - lidocaína, combinaciones con
aire medicinal sintetico solgroup 21,75% v/v gas comprimido medicinal
sol france sucursal en espana - oxigeno - gas comprimido medicinal - 21,75% v/v - oxigeno 21,75 % v/v - aire medicinal
aranesp
amgen europe b.v. - darbepoetin alfa - anemia; cancer; kidney failure, chronic - otros antianémico preparaciones - tratamiento de la anemia sintomática asociada a la insuficiencia renal crónica (irc) en adultos y pacientes pediátricos. tratamiento de la anemia sintomática en pacientes adultos con cáncer no mieloides malignas que reciben quimioterapia.
blincyto
amgen europe b.v. - blinatumomab - leucemia-linfoma linfoblástica de células precursoras - agentes antineoplásicos - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.